{"organizations": [], "uuid": "79b9d70e0df5c9da2ed26c75e617ba47bb885625", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180530&t=2&i=1267400739&w=1200&r=LYNXNPEE4T0F4", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-drug-fasenra-fails-to-achieve-main-goal-in-copd-trial-idUKKCN1IV0M3", "country": "US", "domain_rank": 408, "title": "AstraZeneca drug Fasenra fails to achieve main goal in COPD trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-30T09:50:00.000+03:00", "replies_count": 0, "uuid": "79b9d70e0df5c9da2ed26c75e617ba47bb885625"}, "author": "", "url": "https://uk.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-drug-fasenra-fails-to-achieve-main-goal-in-copd-trial-idUKKCN1IV0M3", "ord_in_thread": 0, "title": "AstraZeneca drug Fasenra fails to achieve main goal in COPD trial", "locations": [], "entities": {"persons": [{"name": "fasenra", "sentiment": "negative"}, {"name": "david goodman", "sentiment": "none"}, {"name": "galathea", "sentiment": "none"}, {"name": "reuters/stefan wermuth", "sentiment": "none"}, {"name": "justin george varghese", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "britain", "sentiment": "none"}], "organizations": [{"name": "astrazeneca", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "european union", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "copd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 30, 2018 / 6:53 AM / Updated 10 hours ago AstraZeneca drug Fasenra fails to achieve main goal in COPD trial Reuters Staff 1 Min Read\n(Reuters) - AstraZenecaâ€™s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD). FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, Britain April 28, 2014. REUTERS/Stefan Wermuth /File Photo\nThe drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.\nFasenra failed to meet its target in the final-stage trial, named Galathea, this month. Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman", "external_links": [], "published": "2018-05-30T09:50:00.000+03:00", "crawled": "2018-05-30T12:18:42.034+03:00", "highlightTitle": ""}